Analysis – Page 153 – Goldea Capital

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic castration-resistant prostate cancer (mCRPC), suggest a potentially differentiated profile compared to approved radiopharmaceuticals Aktis to hold conference call on Wednesday, May 27, 2026, at 8:00 a.m. ET with leading clinical investigators, Oliver Sartor, M.D., and Timothy Yap, MBBS, Ph.D., to discuss resultsBOSTON, May 21, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today...

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the “Offering”). “Yesterday’s capital raise helps the Company prepare for key milestones anticipated in the next year,” said Christer Rosén, Chairman and CEO of Jupiter...

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose dependent and manageable AE profile, no new safety signals observed Webcast on Thursday, May 21, 2026 at 5:30 pm EDTCAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director,...

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Written by Customer Service on May 21, 2026. Posted in Public Companies.

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. “Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a...

Abcourt announces its financial results for the quarter ended March 31, 2026

Written by Customer Service on May 21, 2026. Posted in Earnings Releases And Operating Results.

ROUYN-NORANDA, Quebec, May 21, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB : ABMBF) announces its financial results for the third quarter ended March 31, 2026. All monetary values in this press release are expressed in Canadian dollars, unless otherwise indicated. Financial statements and management discussion and analysis are available on SEDAR+. Summary of financial results(In dollars) Three months ended March 31, Nine months ended March 31, 2026 2025 2026 2025 Revenues 7,877,554 – 12,766,703 – Costs of sales 12,779,778 – 24,457,126 – Tax credit resources (1,032,250 ) – (3,288,901 ) – Loss from mining operations (3,869,974 ) – (8,401,522 ) – Administration expenses 1,469,001 1,068,917 3,646,730 2,499,582 Care...

Banqup delivers 40,3% y/y growth in subscription revenue in Q1 2026

Written by Customer Service on May 21, 2026. Posted in Earnings Releases And Operating Results.

La Hulpe, Belgium – 21 May 2025, 22:30 CEST – REGULATED INFORMATION – Banqup Group SA, (Euronext: BANQ) (Banqup, Company), a leading provider of integrated financial workflow management solutions, publishes its business update for the first quarter of 2026. Key HighlightsSolid Group revenue1,2 growth of 5,0% y/y from € 12,5m in Q1 2025 to € 13,1m in Q1 2026. This was primarily driven by strong growth momentum in digital revenue1 (+14,4% y/y). Banqup’s ARR Digital Services Revenue increased by 12,7% y/y, reaching € 47,0m at the end of March 2026. Completed divestment of Baltic Activities to Fitek Oü on 16 March 2026, aligning with Banqup’s strategy to streamline its operations into a pure-play SaaS company. Including proceeds from the sale, liquidity as of 31 March 2026 stands at € 8,6m. Launched Value Creation Plan to drive cost optimisations...

OFA Group Transitions to U.S. Domestic Issuer Status; Reaffirms United States as the Center of Its Growth Strategy

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Torrance, California, May 21, 2026 (GLOBE NEWSWIRE) — OFA Group (NASDAQ: OFAL) (“OFA Group” or the “Company”) today announced that, effective April 1, 2026, the Company ceased to qualify as a “foreign private issuer” within the meaning of Rule 405 under the Securities Act of 1933 and Rule 3b-4 under the Securities Exchange Act of 1934, and now reports as a U.S. domestic issuer under the Securities and Exchange Commission’s rules applicable to domestic registrants. The transition reflects the Company’s evolution over the past year and the geographic concentration of its shareholders, leadership, operations, and revenue in the United States. While OFA Group remains incorporated in the Cayman Islands and maintains a subsidiary in Hong Kong, the Company’s principal executive offices,...

Announcement from Eimskip: Agreement between SA (on behalf of Eimskip) and the Seafarers Union of Iceland (on behalf of harbor employees)

Written by Customer Service on May 21, 2026. Posted in Public Companies.

The Confederation of Icelandic Enterprise (SA), on behalf of Eimskip, and the Seafarer’s Union of Iceland (SÍ) have entered into an agreement concerning harbor employees at Sundahöfn. The strike previously announced by SÍ, which was scheduled to commence on 26 May 2026, has been withdrawn. Under the agreement, negotiations on a collective wage agreement will be deferred until 31 October 2026 while a competency analysis of port operations is carried out. Embargo on strikes will apply during this period. In parallel, work has commenced on the implementation of a formal competency-based pay system for harbor employees. The system will be based on an objective job evaluation framework, whereby employee competence, skills and responsibilities form the basis for more efficient wage setting and clearer salary progression. The Education and Training...

Genco Shipping & Trading Limited Files Investor Presentation and Urges Shareholders to Vote for the Company’s Highly Qualified Nominees and Reject Diana’s Inadequate Tender Offer

Written by Customer Service on May 21, 2026. Posted in Public Companies.

Highlights Genco’s Proven Comprehensive Value Strategy Delivering Superior Returns and Significant Momentum Underway to Capture Upside Diana’s Offer Remains Inadequate and its Handpicked Director Nominees Pose Significant Risks to Genco Shareholders’ Investment Genco Urges Shareholders to Vote “FOR” the Re-Election of Genco’s Nominees on the WHITE Proxy Card Today – and “WITHHOLD” on Diana’s Nominees Reminds Shareholders Not to Tender Their Shares into Diana’s Tender Offer Presentation and Information on How to Vote Available at www.GencoDrivesSuperiorReturns.com NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today posted an investor presentation in connection...

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Written by Customer Service on May 21, 2026. Posted in Public Companies.

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MNHosting 1×1 meetings on Thursday, May 28th William Blair 46th Annual Growth Stock Conference – Chicago, ILPresentation on Wednesday, June 3rd at 3:20 p.m. Central TimeInterested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of the company website at: www.adaptivebiotech.com. About Adaptive Biotechnologies Adaptive Biotechnologies...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals